Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Decitabine improves platelet recovery by down-regulating IL-8 level in MDS/AML patients with thrombocytopenia.

Zhang W, Liu C, Wu D, Liang C, Zhang L, Zhang Q, Liu Y, Xia M, Wang H, Su P, Feng S, Han M, Zhou J, Wang F, Jiang E.

Blood Cells Mol Dis. 2019 May;76:66-71. doi: 10.1016/j.bcmd.2019.02.003. Epub 2019 Feb 20. No abstract available.

PMID:
30846359
2.

Prognostic Significance of Platelet Recovery in Myelodysplastic Syndromes With Severe Thrombocytopenia.

Tang Y, Zhang X, Han S, Chu T, Qi J, Wang H, Tang X, Qiu H, Fu C, Ruan C, Wu D, Han Y.

Clin Appl Thromb Hemost. 2018 Oct 8:1076029618802363. doi: 10.1177/1076029618802363. [Epub ahead of print]

PMID:
30296835
3.

Thrombopoietin mimetics for patients with myelodysplastic syndromes.

Dodillet H, Kreuzer KA, Monsef I, Skoetz N.

Cochrane Database Syst Rev. 2017 Sep 30;9:CD009883. doi: 10.1002/14651858.CD009883.pub2. Review.

PMID:
28962071
4.

Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes.

Ding K, Fu R, Liu H, Nachnani DA, Shao ZH.

Oncol Lett. 2016 Apr;11(4):2347-2352. Epub 2016 Feb 23.

5.

[Clinical observation of decitabine-treating patients with myelodysplastic syndrome and acute myeloid leukemia].

Yang H, Zhu HY, Jiang MM, Wang QS, Han XP, Huang WR, Jing Y, Wang SH, Zhang SS, Mei JH, Yu L.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Feb;21(1):121-5. doi: 10.7534/j.issn.1009-2137.2013.01.025. Chinese.

PMID:
23484704
6.

Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.

Mittelman M, Platzbecker U, Afanasyev B, Grosicki S, Wong RSM, Anagnostopoulos A, Brenner B, Denzlinger C, Rossi G, Nagler A, Garcia-Delgado R, Portella MSO, Zhu Z, Selleslag D.

Lancet Haematol. 2018 Jan;5(1):e34-e43. doi: 10.1016/S2352-3026(17)30228-4. Epub 2017 Dec 11.

PMID:
29241762
7.

Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia.

Psaila B, Bussel JB, Frelinger AL, Babula B, Linden MD, Li Y, Barnard MR, Tate C, Feldman EJ, Michelson AD.

J Thromb Haemost. 2011 Nov;9(11):2302-10. doi: 10.1111/j.1538-7836.2011.04506.x.

8.

Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.

Pan F, Peng S, Fleurence R, Linnehan JE, Knopf K, Kim E.

Clin Ther. 2010 Dec;32(14):2444-56. doi: 10.1016/j.clinthera.2010.12.003.

PMID:
21353113
9.

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.

Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM.

Cancer. 2015 Feb 15;121(4):556-61. doi: 10.1002/cncr.29085. Epub 2014 Oct 21.

10.

Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.

Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, O'Brien S, Fullmer A, Cortes JE, Wierda W, Kantarjian H.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):131-8. doi: 10.1016/j.clml.2012.11.001. Epub 2012 Dec 21.

11.

The effect of decitabine on megakaryocyte maturation and platelet release.

Wang J, Yi Z, Wang S, Li Z.

Thromb Haemost. 2011 Aug;106(2):337-43. doi: 10.1160/TH10-11-0744. Epub 2011 Jun 28.

PMID:
21713321
12.

A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.

Kirschbaum M, Gojo I, Goldberg SL, Bredeson C, Kujawski LA, Yang A, Marks P, Frankel P, Sun X, Tosolini A, Eid JE, Lubiniecki GM, Issa JP.

Br J Haematol. 2014 Oct;167(2):185-93. doi: 10.1111/bjh.13016. Epub 2014 Jul 8.

13.

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.

Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW.

J Clin Oncol. 2011 May 20;29(15):1987-96. doi: 10.1200/JCO.2010.30.9245. Epub 2011 Apr 11.

PMID:
21483003
14.

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.

Greenberg PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J.

Leuk Lymphoma. 2013 Feb;54(2):321-8. doi: 10.3109/10428194.2012.713477. Epub 2012 Nov 15.

PMID:
22906162
15.

Decitabine in the treatment of myelodysplastic syndromes.

Saba HI.

Ther Clin Risk Manag. 2007 Oct;3(5):807-17.

16.

[Therapeutic efficacies of decitabine application prior to hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia].

Zhou J, Wang J, Liu H, Zheng H, Ma L, Wang P, Yan S, Wu D, Fu C, Qiu H, Tang X, Jin Z, Han Y, Miao M.

Zhonghua Yi Xue Za Zhi. 2015 Mar 31;95(12):920-4. Chinese.

PMID:
26081055
17.

Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Cashen AF, Shah AK, Todt L, Fisher N, DiPersio J.

Cancer Chemother Pharmacol. 2008 Apr;61(5):759-66. Epub 2007 Jun 13.

PMID:
17564707
18.
19.

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.

Giagounidis A, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Hu K, Woodard P, Yang AS, Kantarjian HM.

Cancer. 2014 Jun 15;120(12):1838-46. doi: 10.1002/cncr.28663. Epub 2014 Apr 4.

20.

Supplemental Content

Support Center